ArriVent BioPharma, Inc. (AVBP) stock
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.69−0.87 (-7.53%)
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
ArriVent BioPharma cash
Cash and short-term investments held at the end of each period.
ArriVent BioPharma's cash was $373.12M at Jun 30, 2026. For fiscal 2025 it was $312.82M, up 42.9% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $312.82M | +42.9% |
| FY2024 | Dec 31, 2024 | $218.86M | +45.5% |
| FY2023 | Dec 31, 2023 | $150.39M | -7.9% |
| FY2022 | Dec 31, 2022 | $163.37M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $373.12M | +58.3% |
| Q1 FY2026 | Mar 31, 2026 | $326.38M | +85.4% |
| Q4 FY2025 | Dec 31, 2025 | $312.82M | +42.9% |
| Q3 FY2025 | Sep 30, 2025 | $300.27M | +6.2% |
| Q2 FY2025 | Jun 30, 2025 | $235.69M | -21.1% |
| Q1 FY2025 | Mar 31, 2025 | $176.08M | -44.5% |
| Q4 FY2024 | Dec 31, 2024 | $218.86M | +45.5% |
| Q3 FY2024 | Sep 30, 2024 | $282.86M | +100.1% |
| Q2 FY2024 | Jun 30, 2024 | $298.67M | +89.2% |
| Q1 FY2024 | Mar 31, 2024 | $317.39M | +65.8% |
| Q4 FY2023 | Dec 31, 2023 | $150.39M | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $141.36M | – |
| Q2 FY2023 | Jun 30, 2023 | $157.83M | – |
| Q1 FY2023 | Mar 31, 2023 | $191.46M | – |
| Q4 FY2022 | Dec 31, 2022 | $163.37M | – |
See a number that looks wrong?